Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Mechanism, Clinical Outcome and Therapeutic Intervention of Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive

Next Previous
Trial Profile

The Mechanism, Clinical Outcome and Therapeutic Intervention of Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Favipiravir (Primary) ; Chloroquine diphosphate; Colistimethate sodium; Hydroxychloroquine; Umifenovir
  • Indications COVID 2019 infections
  • Focus Therapeutic Use

Most Recent Events

  • 01 Aug 2021 Primary endpoint (Viral nucleic acid test negative conversion rate) has been met according to the results published in the International Immunopharmacology
  • 01 Aug 2021 Status changed from recruiting to completed.
  • 01 Aug 2021 Results assessing efficacy and safety of favipiravir published in the International Immunopharmacology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top